Changes in access to care from 2010 to 2016 were evaluated.
Patients with cancer may face differences in outcome depending on risk adjustment based on Medicare administrative data.
Soaring costs for cancer drugs are detrimental to patient care in the United States, say a group of oncologists.
Patient demographics and cancer type are major contributing factors for the variation in rates of insurance coverage.
Exact Sciences Corp., maker of Cologuard, announced that several insurers are now covering the non-invasive colon cancer at-home test.
Uninsured patients may be charged anywhere from two to 43 times what private insurance plans or Medicare pay for chemotherapy medications.
Representatives from ASCO held a Congressional briefing to detail their new report's findings.
Medicare payments influenced by postoperative complications, cost of index hospitalization in cancer patients.
ASCO issued a new policy statement that outlines nine specific recommendations to reform Medicaid and improve treatment for low-income patients with cancer.
Annual low-dose computed tomography (CT) lung cancer screen for high-risk individuals will be covered by Medicare.
'Extra Help' program leads to more women on hormone therapy for breast cancer treatment.
Chemotherapy pattern findings based on analysis before and after the Medicare Modernization Act.
Findings among Medicare lung cancer screening beneficiaries at high-risk due to past smoking.
Those with non-Medicaid insurance more likely to have surgery, radiation, and live longer.
Millions signing up for Medicaid to comply with federal health care law.
Due to ACA, more than 25.4 million Original Medicare beneficiaries received at least one free preventive service in 2013
Unless the federal budget sequester is resolved, the impacts to oncology and biomedical research in 2014 could be long-lasting and severe.
Mass cancellations of physicians in Medicare Advantage plans in many states prompts protests.
Insurance enrollment deadline is extended while White House pledges to double capacity of HealthCare.gov website by the end of month.
Many will benefit from Medicaid expansion under the Affordable Care Act, but some will still fall through the cracks.
Tax credits will benefit low and moderate earners.
HHS report finds health insurance premiums will be even less than expected.
Authors of a study point to previous rulings and scientific advances that will minimize the impact of the Supreme Court's ruling that human genes cannot be patented.
In pediatric cancer patients who receive medications at home, the rate of errors is 3.6 with injury per 100 patients, according to a study published online in Pediatrics.
For young women with breast cancer, a longer treatment delay time is associated with decreased survival; and women with early-stage breast cancer with Medicaid are more likely to undergo mastectomy than those with private insurance.
Among Medicaid beneficiaries diagnosed with head and neck cancer, considerable racial disparities exist in treatment patterns and survival.
The impact of sequestration will have far-reaching consequences in health care, according to a perspective piece published online March 20 in the New England Journal of Medicine.
Budget sequestration, which is expected to reduce federal spending, is likely to result in a $120 million loss in grant funding for the nation's 1,200 community health centers in 2013.
Major challenges exist for hospitals with respect to publicly reported cancer metrics, according to research presented at SSO 2013.
Although it would be reasonable to assume that healthcare professionals regularly treat their patients with evidence-based therapies and medicines, healthcare costs may demonstrate otherwise.
Sign Up for Free e-newsletters
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|
|Renal Cell Carcinoma||Regimens||Drugs|
Cancer Therapy Advisor Articles
- BRCA1/Shieldin Double Mutations May Signal Resistance to PARP Inhibitors
- Study Analyzing Postmarketing Data on Breast Implant Safety Sparks FDA Response
- Higher-Dose Immunoglobulin Replacement Therapy in Chronic Lymphocytic Leukemia
- Beyond BRCA: New Predisposition Genes Linked to Breast, Ovarian Cancers
- Finding Clinical Trials in Cancer
- Adding Nintedanib Did Not Improve Survival in Lung Cancer Subtype
- The Identification of a Potential Early Plasma Biomarker for Kidney Cancer
- Pembrolizumab Plus Chemotherapy Extended Survival Longer Than Chemotherapy Alone: Study
- Combining Chemotherapy With Checkpoint Inhibitors Extends Overall Survival in ES-SCLC
- In a Head-to-Head Battle, Brigatinib Appears to Best Crizotinib